Finn RS - Search Results

1

The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study.

Finn RS, Crown JP, Lang I, Boer K, Bondarenko IM, Kulyk SO, Ettl J, Patel R, Pinter T, Schmidt M, Shparyk Y, Thummala AR, Voytko NL, Fowst C, Huang X, Kim ST, Randolph S, Slamon DJ. Finn RS, et al. Lancet Oncol. 2015 Jan;16(1):25-35. doi: 10.1016/S1470-2045(14)71159-3. Epub 2014 Dec 16. Lancet Oncol. 2015. PMID: 25524798 Clinical Trial.

2

The effect of HER-2/neu overexpression on chemotherapeutic drug sensitivity in human breast and ovarian cancer cells.

Pegram MD, Finn RS, Arzoo K, Beryt M, Pietras RJ, Slamon DJ. Pegram MD, et al. Among authors: finn rs. Oncogene. 1997 Jul 31;15(5):537-47. doi: 10.1038/sj.onc.1201222. Oncogene. 1997. PMID: 9247307

3

Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 receptor and DNA-reactive drugs.

Pietras RJ, Pegram MD, Finn RS, Maneval DA, Slamon DJ. Pietras RJ, et al. Among authors: finn rs. Oncogene. 1998 Oct 29;17(17):2235-49. doi: 10.1038/sj.onc.1202132. Oncogene. 1998. PMID: 9811454

4

Biologic effects of heregulin/neu differentiation factor on normal and malignant human breast and ovarian epithelial cells.

Aguilar Z, Akita RW, Finn RS, Ramos BL, Pegram MD, Kabbinavar FF, Pietras RJ, Pisacane P, Sliwkowski MX, Slamon DJ. Aguilar Z, et al. Among authors: finn rs. Oncogene. 1999 Oct 28;18(44):6050-62. doi: 10.1038/sj.onc.1202993. Oncogene. 1999. PMID: 10557094

5

Monoclonal antibody therapy for breast cancer: herceptin.

Finn RS, Slamon DJ. Finn RS, et al. Cancer Chemother Biol Response Modif. 2003;21:223-33. doi: 10.1016/s0921-4410(03)21010-3. Cancer Chemother Biol Response Modif. 2003. PMID: 15338747 Review. No abstract available.

6

EGF activates intracellular and intercellular calcium signaling by distinct pathways in tumor cells.

Bryant JA, Finn RS, Slamon DJ, Cloughesy TF, Charles AC. Bryant JA, et al. Among authors: finn rs. Cancer Biol Ther. 2004 Dec;3(12):1243-9. doi: 10.4161/cbt.3.12.1233. Epub 2004 Dec 14. Cancer Biol Ther. 2004. PMID: 15611621

7

Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells.

Konecny GE, Pegram MD, Venkatesan N, Finn R, Yang G, Rahmeh M, Untch M, Rusnak DW, Spehar G, Mullin RJ, Keith BR, Gilmer TM, Berger M, Podratz KC, Slamon DJ. Konecny GE, et al. Cancer Res. 2006 Feb 1;66(3):1630-9. doi: 10.1158/0008-5472.CAN-05-1182. Cancer Res. 2006. PMID: 16452222

8

Dasatinib, an orally active small molecule inhibitor of both the src and abl kinases, selectively inhibits growth of basal-type/"triple-negative" breast cancer cell lines growing in vitro.

Finn RS, Dering J, Ginther C, Wilson CA, Glaspy P, Tchekmedyian N, Slamon DJ. Finn RS, et al. Breast Cancer Res Treat. 2007 Nov;105(3):319-26. doi: 10.1007/s10549-006-9463-x. Epub 2007 Feb 1. Breast Cancer Res Treat. 2007. PMID: 17268817

9

Activity of lapatinib a novel HER2 and EGFR dual kinase inhibitor in human endometrial cancer cells.

Konecny GE, Venkatesan N, Yang G, Dering J, Ginther C, Finn R, Rahmeh M, Fejzo MS, Toft D, Jiang SW, Slamon DJ, Podratz KC. Konecny GE, et al. Br J Cancer. 2008 Mar 25;98(6):1076-84. doi: 10.1038/sj.bjc.6604278. Epub 2008 Mar 11. Br J Cancer. 2008. PMID: 18334972 Free PMC article.

10

Targeting Src in breast cancer.

Finn RS. Finn RS. Ann Oncol. 2008 Aug;19(8):1379-1386. doi: 10.1093/annonc/mdn291. Epub 2008 May 16. Ann Oncol. 2008. PMID: 18487549 Free article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

246 results

Search Page